|
|
|
|
|
|
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date16 Oct 1981 |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
Active Indication- |
Inactive Indication- |
Drug Highest PhaseNDA/BLA |
First Approval Ctry. / Loc.- |
First Approval Date- |
Phase 3 Study of Alprostadil Continuous Intravenous Infusion to Maintain Clinical Stability in Severe Heart Failure Patients
This is a global multicenter, doubleblind, placebo-controlled, randomized, parallel-group study that compares ALP-1 given in a continuous infusion and placebo in patients with advanced HF. The difference between the two groups for the primary endpoint will be compared after 6 months of study drug therapy (Double-Blind Treatment Phase).
100 Clinical Results associated with Biopeutics Co Ltd
0 Patents (Medical) associated with Biopeutics Co Ltd
100 Deals associated with Biopeutics Co Ltd
100 Translational Medicine associated with Biopeutics Co Ltd